-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to ...
Notes: 1) Observed values, no imputation for missing data. 2) Includes all participants who met the criteria for MetS at baseline and enough MetS component Week 13 data collected to determine MetS ...
Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies ...
Throughout any given year, the National Academies convene hundreds of conferences, workshops, symposia, forums, roundtables, and other gatherings that attract the finest minds in academia and the ...
One in eight adults are living with obesity. Rates of adult obesity have more than doubled since 1990, and rates of adolescent obesity have quadrupled. The number of people living with overweight and ...
Years ago, Florida took an important step to address its obesity rate by creating the Weight Management Pilot Program for ...
SAN DIEGO, Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...
BOSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results